We describe the use of abciximab to prevent rethrombosis of the basilar artery after
transluminal angioplasty. A 60-year-old patient with vertebral basilar insufficiency and acute …

Background—Acute vertebrobasilar occlusion remains a disease with a high mortality even
after treatment by local intra-arterial fibrinolysis. Adjunctive treatment with platelet …

BACKGROUND AND PURPOSE: Fibrinolysis with local intraarterial urokinase infusion for
basilar artery thrombosis has been associated with a low rate of spontaneous symptomatic …

In four patients with acute basilar artery thrombosis, complete arterial recanalization and
good neurologic outcome were achieved with a treatment combining alteplase with tirofiban …

We describe four cases in which abciximab was used as a thrombolytic rescue agent in the
setting of thrombotic events complicating interventional neuroradiologic procedures. After IV …

OBJECTIVE: Abciximab, a platelet glycoprotein IIb/IIIa receptor inhibitor, has been shown to
reduce the risk of ischemic events associated with coronary intervention. However, its role in …

The poor prognosis of basilar artery occlusion is well known. Systemic anticoagulation rarely
prevents a lethal outcome. A new therapeutic approach involves selective perfusion of …

The intravenous administration of abciximab can be used as an adjuvant therapy to facilitate
thrombolysis for acute cerebrovascular occlusion. However, to our knowledge, the …

Thrombolytic therapy of acute basilar artery (BA) thrombosis has been shown to reduce
mortality and avoid a fatal outcome. Objective of this study was to investigate the long-term …

✓ A case is presented of severe atherosclerosis of the basilar artery, successfully treated
with percutaneous transluminal balloon angioplasty. Crescendo daily transient ischemic …